Clinician-directed low-dose plans Licensed US practitioners Free and discreet delivery

Microdosing a GLP-1 medication is not an FDA approved regimen. Semaglutide and tirzepatide are approved with specific titration schedules toward target maintenance doses, and the published trial evidence was generated at those doses. What is described on this page is individualized prescribing at the low end of the dose range, decided by a licensed practitioner for one patient at a time. It is a clinician-directed maintenance approach, not a recognized standard of care and not a shortcut around the approved treatment path. Never adjust your own dose, split a vial, or change a schedule without your practitioner.

Definition

Microdosing means using a GLP-1 medicine at a dose below the standard maintenance target, deliberately and under clinical supervision.

To make that concrete: the approved weight management ladder for semaglutide steps from 0.25mg weekly up to 2.4mg, and for tirzepatide from 2.5mg up to 15mg. The lowest rungs are labeled as starting doses whose job is to let the gut adapt, not to treat. Society's microdose plans sit below even those starting doses, at 0.05mg to 0.5mg once weekly for either molecule.

The term itself comes from patients and from telehealth marketing, not from the drug labels or from clinical guidelines. There is no official definition and no agreed threshold.

What sits underneath it is an ordinary and well-established principle of prescribing: use the lowest dose that achieves the clinical goal. Some patients get a meaningful appetite response at 0.25mg of semaglutide or 2.5mg of tirzepatide and never need more. Holding a patient there is a legitimate clinical decision. Calling it microdosing is branding on top of that decision.

Being straight about this is more useful than being persuasive.

What is established. These medicines have a dose-response relationship. In SURMOUNT-1, mean weight reduction at 72 weeks was larger at higher tirzepatide doses (approximately 15% at 5 mg, rising to approximately 20.9% at 15 mg, versus approximately 3.1% for placebo). Lower doses on average produce smaller reductions. Anyone telling you a microdose performs like a full dose is not describing the trial data.

What is also established. Continued treatment is what maintains the result. In the STEP 4 withdrawal trial, participants moved to placebo regained weight while those who continued kept losing. Treatment interruption is followed by regain across this drug class.

What is not established. There is no large randomized trial testing a deliberately sub-therapeutic maintenance dose against a standard maintenance dose after a patient has reached their goal. The question of whether a low dose can hold a result is clinically reasonable and currently unanswered by high-quality evidence.

What that means for you. A microdose plan is a considered clinical decision made with incomplete evidence, with the trade-off stated openly: less medicine, usually fewer side effects, and less certainty about the outcome. If you want the approach with the most evidence behind it, that is standard titration to a maintenance dose.

A microdose plan starts at the same price as the standard plan for the same molecule, so choose one for clinical reasons and not to save money. Every figure above is a starting price, and what you pay depends on the plan your practitioner prescribes.

All plans include the clinician review, your personalized treatment plan, your medication dispensed through US licensed pharmacies, labs, dose adjustments, continuous clinical assistance and free, discreet, expedited delivery. There is no separate consultation fee and no insurance requirement.

There are no long-term contracts, and you can pause, switch or cancel anytime. Read that alongside the refund policy: the first two (2) months of any treatment plan are strictly non-refundable under any circumstances, and cancelling stops future billing cycles rather than refunding charges already processed. Budget for two months before you start.

If you are interested in a microdose approach, or you are already on a GLP-1 and want to move to maintenance, say so in the free-text field at intake. Your practitioner recommends either a microdose plan or standard titration, with the reasoning explained, and escalation stays available if a lower dose stops controlling appetite.

Microdose plans are prescribed, reviewed and adjusted by licensed US practitioners, never self-selected from a menu.

* Individual results may vary, and not all patients will qualify for treatment. Always consult a licensed healthcare provider before starting or modifying any medical treatment.

Society facilitates access to consultations with independent, licensed healthcare providers who evaluate each patient and determine eligibility for treatment. Prescription products require an online medical evaluation. Medications are prescribed by independent physicians and dispensed by licensed U.S. pharmacies or a patient's preferred pharmacy. Only a qualified healthcare provider can determine whether a treatment is appropriate for an individual's specific medical needs.
Providers are licensed in the state where the patient is located at the time of consultation, and availability may vary by state.
Society's services are intended for individuals 18 years of age or older. Age verification may be required as part of the intake process.
‍Society partners with licensed U.S. pharmacies. Certain treatments may include compounded medications, which are not FDA-approved and have not been evaluated by the Food and Drug Administration for safety, efficacy, or quality. Compounded medications may be prescribed by a healthcare provider based on individual patient needs or during periods of drug shortages. FDA-approved GLP-1 medications—such as Ozempic® (semaglutide), Wegovy® (semaglutide), and Zepbound® (tirzepatide)—are not compounded. Society is not affiliated with, endorsed by, or sponsored by the manufacturers of these products. All trademarks and brand names belong to their respective owners.
GLP-1–based treatments may carry risks, including the potential for thyroid C-cell tumors. These medications should not be used by individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Please consult a healthcare provider for complete prescribing and safety information.
Prescription medications are dispensed only when determined appropriate by a licensed healthcare provider following an online medical evaluation. No prescription is guaranteed, and treatment decisions are made solely at the prescriber's clinical discretion.
Statements on this website have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Images shown are for illustrative purposes only; actual product appearance may vary.